Asked about it, she said, "Happy po ako na hinahanap ako. Pero ngayon nandito na po ako. I’m here at MOA, magpe-perform. So I hope nandito rin sila sa labas." (I'm happy that they're looking for me.

The company announced significant advancements in breast cancer treatment, with its drug Enhertu receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the ...

Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, ...

With over 25 years of experience, Dr. Reed has also served as past president of the Mississippi Optometric Association (MOA) and the Southwest Optometric Society. His dedication to the field has ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...